Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated January 6, 2026, reports a significant regulatory milestone. The Japan Ministry of Health, Labour and Welfare (MHLW) has approved Exdensur (depemokimab) for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). This marks the third regulatory approval for the drug, following authorizations from the US FDA and UK MHRA in December 2025.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused exclusively on a product approval announcement and clinical trial results.
Material Changes and Clinical Data
The primary material change is the expansion of Exdensur's commercial footprint into Japan. The approval is based on data from the SWIFT and ANCHOR Phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen:
- Severe Asthma (SWIFT Trials): Depemokimab resulted in a significant reduction in annualized asthma exacerbation rates compared to placebo. SWIFT-1 showed a 58% reduction (rate ratio 0.42), and SWIFT-2 showed a 48% reduction (rate ratio 0.52).
- CRSwNP (ANCHOR Trials): Significant improvements were observed in nasal polyp size and nasal obstruction. ANCHOR-1 showed a treatment difference of -0.7 in nasal polyp score, and ANCHOR-2 showed -0.6.
- Safety Profile: The drug was well-tolerated across trials, with side effect rates and severity similar to placebo.
Outlook, Management Commentary, and Risks
Management Commentary: Kaivan Khavandi, SVP and Global Head of Respiratory, Immunology & Inflammation R&D, stated that the Japan approval could set a new standard of care. The ultra-long-acting nature of the drug (two doses per year) aims to improve patient outcomes and reduce health system burdens by preventing exacerbations and managing debilitating symptoms.
Outlook and Pipeline:
- Regulatory Status: Exdensur has received a positive CHMP opinion in the EU and is under review in China and other countries.
- Future Trials: GSK is evaluating depemokimab in Phase III trials for other type 2 inflammatory diseases, including eosinophilic granulomatosis with polyangiitis (OCEAN), hyper eosinophilic syndrome (DESTINY), and COPD (ENDURA-1, ENDURA-2, VIGILANT).
Risks: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2024 Form 20-F and Q3 2025 results, including regulatory uncertainties and market adoption challenges.
Investor Verification Checklist
- Verify the specific launch timeline and commercialization strategy for Exdensur in the Japanese market.
- Confirm the pricing and reimbursement status of Exdensur in Japan following MHLW approval.
- Monitor the timeline for final EU marketing authorization following the positive CHMP opinion.
- Review upcoming data readouts for the OCEAN, DESTINY, and COPD (ENDURA/VIGILANT) trials to assess the drug's potential market expansion beyond asthma and CRSwNP.
- Check for any updates on the competitive landscape for ultra-long-acting biologics in respiratory diseases.